D-Wave Quantum: A 91.90% Lab Score, a Trimmed $27 Target and a November 10 Print That Must Sort Signal From Substance
Published on 11/04/2026 at 02:41 | Editorial boerse-global.de
D-Wave Quantum handed investors three distinct pieces of news in quick succession — a research result, a non-binding partnership and a revised analyst target — and none of them answers the question that matters most: how much commercial substance sits behind the technology's promise. The next hard checkpoint arrives on November 10, 2026, when the company reports third-quarter results before the market opens.
A high hit rate, with caveats attached
The most eye-catching item is a lung-cancer prediction model built by researchers at Florida Atlantic University, who ran it on D-Wave's annealing quantum computers and achieved 91.90% accuracy on the quantum hardware. The figure is striking. The researchers themselves labelled the findings preliminary, and the dataset used had been expanded with additional data. Both qualifications belong to any fair reading of the result and should not be buried beneath the headline number.
For shareholders, the work points to possible applications of the technology. It does not constitute proof of commercial exploitation. What the study establishes concerns the model under examination and the research conditions surrounding it.
A handshake in Korea, not a contract
Roughly a week ago, D-Wave and LG CNS signed a letter of intent to pursue quantum-optimization applications and joint marketing opportunities in South Korea and international markets. The agreement is explicitly non-binding. Target areas include manufacturing, telecommunications, financial services and retail — a broad direction for collaboration rather than a concluded commercial deal.
That distinction is central to valuation: interest in working together and binding economic commitments are not the same thing. Counting the number of possible application fields does not answer the question of how much economic weight the partnership will ultimately carry. The memorandum is a starting point for future progress, not a substitute for evidence of it.
Should investors sell immediately? Or is it worth buying D-Wave Quantum?
A customer's prize, and what it does not prove
Separately, D-Wave customer Shionogi won the quality-of-life category of the NEDO Quantum Computing Challenge for research into quantum computing in drug development. The award recognizes a research approach. It does not demonstrate any revenue or profit contribution for D-Wave.
B. Riley keeps its buy, trims its number
Media reports indicate that Craig Ellis of B. Riley Securities cut his price target to $27 from $40, while maintaining his buy recommendation. That combination is neither a full withdrawal of confidence nor an unambiguously positive message. The retained buy rating signals optimism about the company's direction; the lower target shows the analyst has scaled back his valuation yardstick. Anyone reading only the recommendation misses the more cautious assessment.
The cut was reported against a backdrop of weakness in quantum-computing and technology stocks. No specific explanation for the share price's recent move can be derived from it. The analyst action is best read as an expression of tempered expectations rather than as evidence of a particular trigger for the advance.
The tape versus the thesis
The stock gained 2.8% yesterday, with another report putting the day's rise at 3.0%. Either way, a single session's movement says nothing about how far the commercial implementation of the described applications has actually progressed. A friendly price reaction or an individual positive headline should not dominate the valuation debate.
November 10 and beyond
The announced release of third-quarter 2026 results on November 10, 2026, before the open, offers the next concrete test — a chance to re-anchor the discussion in business performance. Research results and statements of intent can be weighed economically against such figures, provided investors keep claims about technical possibility separate from reported business numbers.
D-Wave has also announced investor-conference appearances following the results, scheduled for November 11–19 and again on December 2 and 3, 2026. What matters is which concrete business results accompany the application outlook. The company offers grounds for confidence, but no reason to flatten the differences between research, intention and commercial success.
Ad
D-Wave Quantum Stock: New Analysis - 4 November
Fresh D-Wave Quantum information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
